Lack of a Protein in Lung Tumors May Increase Risk of Death
A study of human lung tumors indicates that lung cancer patients who lack a particular protein may do more poorly after surgery than those with normal levels of that same protein.
If the findings are verified in a clinical trial, the absence of the protein might be used to identify lung cancer patients who need more aggressive therapy.
The protein is the product of a gene called Olig1, which previously has not been linked with lung cancer, and it is located in a chromosome region that is often lost in the tumor cells of many lung-cancer patients.
The study, led by researchers at the Ohio State University Comprehensive Cancer Center, is published in the March 27 issue of the journal PLoS Medicine.
The research examined tumors from people with non-small cell lung cancer (NSCLC), the most common form of lung cancer. It sought to identify genes that are turned off, or silenced, by a process called aberrant DNA methylation.
The study wanted to learn if the pattern of silenced genes could distinguish between two subtypes of NSCLC, adenocarcinoma and squamous cell carcinoma.
The research identified 47 genes that together can differentiate between the two lung cancer subtypes. It also found that the silencing of the Olig1 gene